Immunotherapy for metastatic prostate cancer: Where are we at with sipuleucel-T?

Expert Opinion on Biological Therapy

Volumn 11, Issue 1, 2011, Pages 99-108

  Lü, Chen ^a   Williams, Andrew K ^a   Chalasani, Venu ^a   Martínez, Carlos H ^a   Chin, Joseph ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

APC8015; cancer vaccine; immunotherapy; prostate cancer; provenge; sipuleucel T

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ACID PHOSPHATASE PROSTATE ISOENZYME ANTIBODY; ANDROGEN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CANCER VACCINE; CD14 ANTIGEN; CD19 ANTIGEN; DOCETAXEL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; HYDRAZINE SULFATE; INTERCELLULAR ADHESION MOLECULE 1; KETOCONAZOLE; LACTATE DEHYDROGENASE; PA 2024; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROTEIN ANTIBODY; PROVENGE; SURAMIN; UNCLASSIFIED DRUG;

ANEMIA; ANTIBODY RESPONSE; ASTHENIA; B LYMPHOCYTE; BODY WEIGHT; BONE METASTASIS; BRAIN ISCHEMIA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER SURGERY; CANCER SURVIVAL; CASTRATION; CD3+ T LYMPHOCYTE; CHILL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DENDRITIC CELL; DRUG APPROVAL; DRUG CONTROL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSPNEA; FATIGUE; FEVER; FLU LIKE SYNDROME; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; GLEASON SCORE; HEADACHE; HORMONE DEPENDENCE; HUMAN; HYPERHIDROSIS; HYPERTENSION; INFECTION; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKAPHERESIS; LYMPHOCYTE PROLIFERATION; METASTASIS; MONOCYTE; MYALGIA; NATURAL KILLER CELL; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; PROTEINURIA; REVIEW; T LYMPHOCYTE; TREMOR; VOMITING;

CANCER VACCINES; HUMANS; IMMUNOTHERAPY; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; TISSUE EXTRACTS;

HARNESS;

EID: 78650055750     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2011.538677     Document Type: Review

References (28)

1. SEER stat fact sheets - cancer of the prostate. National Cancer Institute, Bethesda, MD; 2010. Available from: Http://seer.cancer.gov/statfacts/ html/ prost.html. [Last accessed 8 November 2010]
2. CancerStats key facts on cancer. Cancer research UK, London, UK; 2010. Available from: Http://info. cancerresearchuk.org/cancerstats/keyfacts/ index.htm. [Last accessed 8 November 2010]
3. Canadian cancer statistics. Canadian Cancer Society, Toronto: Ontario 2010. Available from: Http://www.cancer. ca/canada-wide/about cancer/cancer statistics/Canadian cancer statistics.aspx? sc-lang=en. [Last accessed 8 November 2010]
4. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998;339:1036-42
5. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20
6. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12
7. Pijpers F, Faint R, Saini N. Therapeutic cancer vaccines. Nat Rev Drug Discov 2005;4:623-4
8. Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000;18:3894-903
9. Burch PA, Breen JK, Buckner JC, et al. Priming tissue-specific cellular immunity in a Phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 2000;6:2175-82
10. Saika T, Satoh T, Kusaka N, et al. Route of administration influences the antitumor effects of bone marrow-derived dendritic cells engineered to produce interleukin-12 in a metastatic mouse prostate cancer model. Cancer Gene Ther 2004;11:317-24
11. Rini BI, Weinberg V, Fong L, et al. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer 2006;107:67-74
12. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994;179:1109-18
13. Klein C, Bueler H, Mulligan RC. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines. J Exp Med 2000;191:1699-708
14. Burch PA, Croghan GA, Gastineau DA, et al. Immunotherapy (APC8015, provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: A Phase 2 trial. Prostate 2004;60:197-204
15. Taussig MJ. Induction of hapten-specific B cell tolerance by low doses of hapten-carrier conjugate. Nature 1973;245:34-6
16. Beinart G, Rini BI, Weinberg V, Small EJ. Antigen-presenting cells 8015 (provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer. Clin Prostate Cancer 2005;4:55-60
17. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled Phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24:3089-94
18. Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, Phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009;115:3670-9
19. Schellhammer PF, Higano CS, Berger ER, et al. A randomized, double-blind, placebo-controlled, multi-center, phase III trial of sipuleucel-T in men with metastatic, androgen independent prostatic adenocarcinoma (AIPC). 2009 AUA Annual Meeting, Late-Breaking Science Forum [abstract]. 2009. Available from: Http://www. aua2009.org/program/lba/lba9.pdf [Last accessed 8 November 2010]
20. Kantoff PW, Higano CS, Shore N, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22
21. Dendreon Announces FDA Advisory Committee Reviewed Provenge® for Hormone Refractory Prostate Cancer. Seattle, Denderon Corp., Washington; 2007. Available from: Http://investor. dendreon.com/phoenix.zhtml? c=120739&p=irol-newsArticle&ID=1369743&highlight=Provenge [Last accessed 8 November 2010]
22. Provenge (sipuleucel-T) active cellular immunotherapy treatment of metastatic prostate cancer after failing hormone therapy. ClinicalTrials.gov, Bethesda, MD; 2010. Available from: Http:// clinicaltrials.gov/ct2/show/ NCT00065442?term= NCT00065442&rank=1 [Last accessed 8 November 2010]
23. Open label study of sipuleucel-T. ClinicalTrials.gov, Bethesda, MD; 2010. Available from: Http://www. clinicaltrials.gov/ct2/show/ NCT00901342?term= dendreon&rank=5. [Last accessed 8 November 2010]
24. To evaluate sipuleucel-T manufactured with different concentrations of PA2024 antigen. ClinicalTrials.gov, Bethesda, MD; 2010. Available from: Http://clinicaltrials. gov/ct2/show/NCT00715078. [Last accessed 8 November 2010]
25. Sipuleucel-T as neoadjuvant treatment in prostate cancer. ClinicalTrials.gov, Bethesda, MD; 2010. Available from: Http://clinicaltrials. gov/ct2/show/NCT00715104? term=NCT00715104&rank=1 [Last accessed 8 November 2010]
26. Provenge (TM) for the treatment of hormone sensitive prostate cancer. ClinicalTrials.gov, Bethesda, MD; 2010. Available from: Http://clinicaltrials. gov/ct2/show/NCT00779402? term=Provenge+%28TM%29+for+the +treatment+of+hormone+sensitive +prostate+cancer.&rank=1
27. Beer TM, Bernstein GT, Corman JM, et al. Randomized trial of active cellular immunotherapy with sipuleucel-T in androgen dependent prostate cancer (ADPC). 2007 ASCO Annual Meeting Proceedings. J Clin Oncol 2007;25(18S):5059
28. Dendreon Presents Updated IMPACT Results Confirming PROVENGE Improves Overall Survival in Patients With Metastatic Castrate-Resistant Prostate Cancer. Seattle, Denderon Corp., Washington; 2007. Available from: Http://investor. dendreon.com/phoenix.zhtml? c=120739&p=irolnewsArticle&ID= 1398598&highlight=. [Last accessed 8 November 2010]